1	Causal association between serum bilirubin and ischemic stroke:
2	Multivariable Mendelian Randomization
3	
4	Jong Won Shin ¹⁾ *, Keum Ji Jung ^{1,2)} *, Heejin Kimm ^{1,2)} , Sun Ha Jee ^{1,2)}
5	1) Department of Epidemiology and Health Promotion, Graduate School of
6	Public Health, Yonsei University, Seoul, Korea
7	2) Institute for Health Promotion, Department of Epidemiology and Health
8	Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea
9	
10	* Both authors contributed equally as first authors.
11	
12	Running title: Serum bilirubin and ischemic stroke
13	
14	Correspondence:
15	Sun Ha Jee, PhD, MPH
16	Department of Epidemiology and Health Promotion, Graduate School of
17	Public Health,
18	50-1 Yonsei-ro, Seodaemun-gu, Seoul 03772, Korea
19	Tel: 82-2-2228-1523, E-mail: jsunha@yuhs.ac
20	
21	
22	
23	
24	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 **Abstract (230)**

BACKGROUND: Past studies have mainly focused on total bilirubin levels, and have
not clearly distinguished between direct and indirect bilirubin, a subgroup of bilirubin.
In this study, the differences between these subgroups were clearly examined, and
the causal association with ischemic stroke was examined in more detail.

METHODS: Utilizing Two sample Multivariable Mendelian randomization (MVMR) analyses, summary data for bilirubin were extracted from the KCPS-II (Korean Cancer Prevention Study-II; n=159,844) and the KoGES (Korean Genome and Epidemiology Study; n=72,299), while ischemic stroke data were derived from the BBJ (Bio Bank Japan; n=201,800).

RESULTS: The crude two-sample MR analysis revealed a significant negative 35 association between total bilirubin and ischemic stroke in KoGES data (odds ratio 36 [OR], 0.86; 95% confidence interval [CI], 0.75-0.98). Subsequent bivariable MR 37 analyses, controlling for lipid profile, also showed significant results. In KCPS-II data, 38 direct bilirubin showed significance in both crude (0.65, 0.43-0.97) and bivariable 39 analyses, while indirect bilirubin demonstrated significant associations in MVMR 40 analyses (0.76, 0.59-0.98), emphasizing its role in mitigating the risk of ischemic 41 42 stroke.

43 **CONCLUSIONS:** Our study establishes a causal association between genetically 44 determined levels of serum bilirubin (total, direct, and indirect) and a reduced risk of 45 ischemic stroke in an Asian population. Notably, the protective effect was 46 predominantly associated with indirect bilirubin. The findings highlight the 47 significance of considering bilirubin subgroup in understanding the mechanisms 48 underlying endogenous antioxidants and its impact on ischemic stroke.

Key Words: bilirubin, ischemic stroke, multivariable mendelian randomization 49

50 **INTRODUCTION**

51

Stroke is a form of oxidative stress-related disease.^{1,2,3} Serum bilirubin levels are 52 widely reported to be inversely related to stroke risk in both Western populations^{4,5} 53 and Asian populations.^{6,7} These studies have been based on serum total bilirubin 54 levels. In other words, it is a result that does not take into account the specific levels 55 of direct bilirubin (conjugated bilirubin) and indirect bilirubin (unconjugated bilirubin) 56 that make up the total bilirubin. In fact, indirect bilirubin levels account for a large 57 proportion of the subgroups of total bilirubin (reference values - total bilirubin: 0.3-1.0 58 59 ma/dl, direct bilirubin: 0-0.3 mg/dl, indirect bilirubin: 0.2-0.8 mg/dl). Aged red blood cells are broken down into heme and globin, and then heme is broken down into iron 60 (Fe2+) and biliverdin. In the process of oxidation to biliverdin (Figure 1), the level of 61 indirect bilirubin acts as a powerful endogenous antioxidant.^{8,9} 62

The First study on total bilirubin and stroke occurrence using genetic information was 63 a case-cohort design of 806 stroke patients that occurred in a subcohort of 4,793 64 subjects in the KCPS-II (Korean Cancer Prevention Study-II). This study, a one-65 sample mendelian randomization (MR) analysis, showed a negative association 66 between total bilirubin and total stroke (HR=0.63, 95% CI 0.30-1.36), but did not 67 show statistically significant results (p=0.240).¹⁰ The second study performed a two-68 sample MR analysis of total bilirubin based on KoGES (Korean Genome and 69 Epidemiology Study; n=25,406) and KCPS-II (n=14,541) biobank data.¹⁰ The results 70 provided evidence for a significant causal association between total bilirubin levels 71 and reduced risk of stroke in the Korean population. In particular, the association 72 was greater for ischemic stroke (OR=0.302) than for total stroke (OR=0.481).¹¹ 73

However, considering only serum total bilirubin, there was insufficient specific evidence to suggest a reduction in stroke risk through bilirubin's role as an endogenous antioxidant.

77 **OBJECTIVES**

- 78 1. We divided bilirubin into subgroups to determine whether each subgroup
 79 plays a role as an endogenous antioxidant.
- We also investigated whether it was possible to suggest the significance of
 causal associations when adjusting for several genetic variables, which was
 not possible in existing MR studies.
- 83

84 **METHODS**

We analyzed total, direct, and indirect bilirubin data from KoGES (n=72,299)¹² and KCPS-II (n=159,844) biobanks¹³ and ischemic stroke from BBJ (BioBank Japn; n=201,800).¹⁴ data was used to perform Two Sample Multivariable MR (MVMR). In other words, MVMR was performed to control blood pressure, fasting blood sugar, and serum lipid levels related to stroke.

90

91 Genetic instruments for serum bilirubin (G-X)

A genetic instrumental variable for serum bilirubin was identified using two Korean biobanks (KCPS-II and KoGES).^{12,13} The selection of instrumental variables for MR analysis was based on the following criteria: First, cases with a *p*-value smaller than the genome-wide significance level identified in the study (*p*-value < $5x10^{-8}$). The second, minor allele frequency (MAF) is greater than 0.01. The third, single nucleotide polymorphism (SNP)s with linkage disequilibrium (LD) relationship were

- excluded (clumping criteria: r^2 0.001 standard). Finally, palindromic (SNP) was excluded from the analysis (MAF > 0.42).
- 100
- 101

102 Genetic associations of SNPs with ischemic stroke (G-Y)

- Summary data used for ischemic stroke were obtained from BBJ.¹⁴ BBJ is a biobank
 composed of 201,800 patient data centered on 66 hospitals nationwide between
 2003 and 2008.
- 106

107 Mendelian randomization

In this study, G-X data on exposure as two-sample MR came from KCPS-II and

109 KoGES. And G-Y data for outcome came from BBJ. The coefficient was estimated

using the inverse variance weighted (IVW) method under the assumption that all

selected SNPs were valid. At this study, coefficient was calculated by calculating the

- 112 coefficient of each SNP according to the wald ratio method and combining it using
- 113 the IVW method.

Multivariable MR (MVMR) analysis was performed controlling for genetic variables of triglyceride (TG), cholesterol (LDL; low density lipoprotein, HDL; high density lipoprotein), systolic blood pressure (SBP), and fasting blood sugar (FBS), which are noted as major causes of stroke. To ensure the validity of instrumental variables, the F-value of each variable was presented in each model.

119

120 Analyses were conducted using the Two Sample MR package in R, version 3.6.0 (R

121 Project for Statistical Computing).

122

123 **RESULTS**

124

This study divided bilirubin into total, direct, and indirect bilirubin and analyzed Mendelian randomization for each of them for their association with the risk of ischemic stroke. In this study, summary data for bilirubin was extracted from KoGES and KCPS-II, respectively, and summary data for ischemic stroke was used from BBJ data.

Table 1 shows crude two-sample MR and MVMR results on the effect of total 130 bilirubin on ischemic stroke. It showed a significant negative association that crude 131 two sample MR analysis between total bilirubin and ischemic stroke in KoGES data 132 (OR, 0.86, 95%CI, 0.75-0.98). In addition, MVMR, controlling for LDL, HDL, and TG, 133 respectively, showed significant results. Additionally, there are borderline significant 134 results in the crude two-sample MR results and in the model controlling LDL from 135 KCPS-II. However, MVMR, controlling for HDL and TG, showed significant results. In 136 the remaining models, a negative association between total bilirubin and ischemic 137 stroke was observed, but it was not significant (Figure 1-A). The F-statistic of total 138 bilirubin and other variables used in the model in Table 1 were all above 10 except 139 for systolic blood pressure (SBP), and the assumption as an instrumental variable 140 was satisfied (Supplementary Table 1). 141

Table 2 shows the crude two sample MR and MVMR results on the effect of direct bilirubin on ischemic stroke. KoGES data analysis showed a significant negative association only in crude two-sample MR (p=0.0493). However, KCPS-II data analysis showed significant results in crude two sample MR, and also showed

significant results in MVMR with LDL, HDL, and TG controlled respectively. The
remaining model showed a negative relationship, but it was not significant (Figure 1B). The F values of direct bilirubin and control variables used in the model in Table 2
were all above 10 except for SBP, and the assumption as an instrumental variable
was satisfied (Supplementary Table 2).

Table 3 showed the crude two sample MR and MVMR results on the effect of indirect 151 bilirubin on ischemic stroke. KoGES results showed a significant negative correlation 152 only in crude two sample MR (P=0.0253). However, in the KCPS-II data analysis, the 153 crude two sample MR showed a borderline significant result, but the MVMR analysis 154 controlling the remaining LDL, HDL, and TG showed a significant result. In addition, 155 MVMR, which simultaneously controlled LDL, HDL, and TG, showed significant 156 results (P=0.0355). This model showed significant results for indirect bilirubin even 157 when SBP or FSG was additionally controlled (right side of Figure 1-C). The F values 158 of indirect bilirubin and control variables used in the model in Table 3 were all above 159 10 except for SBP, and the assumption as an instrumental variable was satisfied 160 (Supplementary Table 3). 161

In the models presented in Tables 1, 2, and 3, the common feature of the other control factors except bilirubin was that only SBP consistently showed a significant causal relationship to the risk of ischemic stroke. However, LDL, TG, and FBS were not significant.

166

167 **DISCUSSION**

168

169 In this study, we showed that genetically determined levels of each bilirubin (total,

direct, and indirect bilirubin) in serum were causally associated with reduced risk of ischemic stroke in an Asian population. In particular, it was demonstrated that only indirect bilirubin had a strong protective effect in MVMR, which controlled for genetic factors related to ischemic stroke.

This study performed two sample MR to investigate the causal relationship between genetically determined levels of circulating serum bilirubin (total, direct, and indirect bilirubin) and the risk of ischemic stroke. In addition, the causal relationship was shown while controlling for genetic variables of TG, cholesterol (HDL, LDL), SBP, and FBS.

Interestingly, while controlling for genetic variables such as TG, cholesterol (HDL, LDL), SBP, and FBS, indirect bilirubin levels reduced the risk of ischemic stroke. On the other hand, for direct bilirubin, a somewhat weaker association was found. These research results are expected to contribute to understanding the mechanisms caused by oxidative stress in the future.

In the metabolic process of bilirubin, heme is broken down by heme oxygenase to 184 produce carbon monoxide (CO), iron (Fe), and biliverdin.^{15,16} In normal, healthy liver 185 cells, biliverdin is converted to bilirubin via biliverdin reductase A (BVRA). Biliverdin 186 reductase exists as two type of isoenzymes. BVRA and biliverdin reductase B 187 (BLVRB) produce bilirubin IX α and bilirubin IX β , respectively.¹⁵ BVRA is critical for 188 adult bilirubin production forming bilirubin IX α , whereas bilirubin IX β is mostly 189 present during fetal development. Bilirubin IXa is insoluble and binds to albumin in 190 191 the blood (indirect bilirubin, unconjugated bilirubin), where it is transported to the liver and conjugated.¹⁵ 192

193 Afterwards, bilirubin is conjugated in hepatocytes by the UGT1A1 UDP-

194 glucuronosyltransferase enzyme (direct bilirubin, conjugated bilirubin) and is
 195 eventually excreted in bile and reaches the intestines.^{16,17}

196 Conjugated bilirubin is isolated by intestinal bacteria and reduced to urobilinoid. In 197 this way, the enzymes and activity sites involved in each bilirubin during the 198 metabolic process are different. Since the manifestation of the disease according to 199 the increase or decrease in each of these levels appears completely different, it is 200 believed that the classification of total bilirubin subgroups will have a significant 201 impact on the results and direction of the research.

In two Sample MR, exposure variables and outcome data are each extracted from two independent biobanks. This is advantageous when exposure and outcome data are not available from the same biobank. This study used serum bilirubin data from KoGES and KCPS-II. For ischemic stroke data, MR analysis could be performed using the same Asian data from BBJ.

Additionally, utilizing multiple samples improves the overall sample size and subsequent precision of causal effect estimates. As a result, we not only re-proved the causal relationship between bilirubin levels and stroke risk reduction in Korean cases in the previous study,^{10,11} but also confirmed the causal relationship between ischemic stroke risk reduction in Japanese as an Asian population.

Evidence from numerous observational studies in humans indicates a strong negative association between serum bilirubin levels and cardiovascular disease. For example, bilirubin has antioxidant properties, including scavenging reactive oxygen species (ROS) and inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, thereby oxidative stress, which is critically involved in the pathogenesis and development of atherosclerosis.^{18,19}

Additionally, serum total bilirubin concentration was negatively associated with arteriosclerosis in Chinese men,²⁰ and in a German population, serum bilirubin levels were observed to be inversely associated with coronary artery calcification and cardiovascular disease.²¹In the Chinese population, serum total bilirubin levels were negatively associated with subclinical cerebral infarction, which increased the risk of transient ischemic attack, symptomatic stroke, and cardiovascular disease.²²

Regarding stroke risk, a cross-sectional study of Americans conducted from 1999 to 2004, the National Health and Nutrition Examination Survey, reported that serum total bilirubin levels were inversely associated with stroke outcomes.²³ Especially in the Korean population, serum bilirubin concentration was estimated to be negatively correlated with ischemic stroke in men.⁶

Additionally, several experimental studies support the results of this study. When 229 bilirubin acts as a ROS scavenger, indirect bilirubin (albumin-bound unconjugated 230 bilirubin) is oxidized to its non-toxic metabolic precursor biliverdin, which is then 231 recycled back to bilirubin by biliverdin reductase.^{19,24,25} In vitro studies have shown 232 that indirect bilirubin (unconjugated bilirubin bound to albumin) is oxidized by O_2 –, 233 OH and HO₂ and that unconjugated bilirubin protects albumin from oxidation by $O_2 -$, 234 OH, HO₂ and ONOO -. Indirect bilirubin can act as an antioxidant by directly 235 scavenging ROS.^{19,25,26} In addition, indirect bilirubin has been shown to inhibit the 236 activity of NADPH oxidase, a major source of ROS in the vascular system, in vitro 237 and in vivo, suggesting that the production of ROS is reduced by indirect 238 bilirubin.^{18,27} Moreover, bilirubin has been shown to interact with other antioxidants to 239 synergistically inhibit lipid peroxidation.^{28,29} Taken together, these experimental 240 findings indicate that indirect bilirubin can function as an antioxidant by interacting 241

synergistically with other antioxidants to scavenge ROS, inhibit NADPH oxidase
activity, and inhibit lipid oxidation.

Bilirubin is a key indicator that continues to be studied today as studies have linked it to the risk of oxidative stress-related diseases in humans, such as cardiovascular disease, including stroke, diabetes, metabolic syndrome, certain cancers, and autoimmune diseases.²⁹ The above research results suggest that specific studies of other oxidative stress-related diseases can be conducted based on the detailed bilirubin index and each bilirubin level presented by controlling various genetic variables.

The strengths and limitations of this study are as follows. The strength is that 251 bilirubin data was obtained from KCPS-II and KoGES data as a Korean biobank for 252 two-sample MR analysis, and stroke data is large-scale data using the Japanese 253 biobank BBJ. Additionally, unlike previous studies, this is the first study to look at the 254 effects of direct and indirect bilirubin in addition to total bilirubin. A limitation is that 255 only ischemic stroke was included in the study, and total stroke and hemorrhagic 256 stroke were not included. However, in previous studies examining bilirubin and 257 stroke, only ischemic stroke showed a significant association. 258

259

260 CONCLUSIONS

This study causally proved that indirect bilirubin is a very significant causal protective factor in the risk of ischemic stroke. However, when comparing systolic blood pressure and indirect bilirubin, which are shown to be the same causal factor although the direction is different, indirect bilirubin has a very wide confidence interval. This implies that the reliability and statistical significance of the estimation

results remain low. In the future, it is believed that research should continue to gain a

267 deeper understanding of the protective effect of indirect bilirubin on ischemic stroke.

Acknowledgements We would like to thank the staff at Korea Medical Institute for their assistance in data collection. We would also like to thank the staff at the other 11 general health examination centers who participated in this study for their assistance in data collection.

272 **Source of Funding** This research was supported by a grant of the Korea Health 273 Technology R&D Project through the Korea Health Industry Development Institute

274 (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI20C0517).

275 Disclosures

276 None.

277 **Contributors** SHJ, KJJ and HK had full access to all of the data in the study and

takes responsibility for the integrity of the data and the accuracy of the data analysis.

279 Study concept and design: SHJ, KJJ and HK. Diagnostic testing and statistical

analysis: SHJ and KJJ.

281 Drafting of the manuscript: JWS and KJJ.

282 Critical revision of the manuscript for important intellectual content: SHJ and HK.

283 Study supervision and organization of the project: SHJ and HK.

Ethical approval This study protocol was approved by the Institutional Review
 Board of the Severance Hospital (approval number: 4-2011-0277).

286

287 ORCID iDs

- 288 Jong Won Shin http:// orcid. org/ 0009-0003-8587-1445
- 289 Keum Ji Jung http:// orcid. org/ 0000-0003-4993-0666
- 290 Heejin Kimm http:// orcid. org/ 0000 0003 4526 0570
- 291 Sun Ha Jee http:// orcid. org/ 0000-0001-9519-3068

292

293 Figure legend

- Figure 1. Causal association between total, direct, and indirect bilirubin and ischemic
- 295 stroke using MVMR

296 **References**

297

- 1. Sierra C, Coca A, Schiffrin EL. Vascular mechanisms in the pathogenesis of stroke.
- ²⁹⁹ Curr Hypertens Rep. 2011;13:200–207. doi: 10.1007/s11906- 011-0195-x

300

2. Allen CL, Bayraktutan U. Oxidative stress and its role in the pathogenesis of
ischaemic stroke. Int J Stroke. 2009;4:461–470. doi: 10.1111/j.17474949.2009.00387.x

304

305 3. Khoshnam SE, Winlow W, Farzaneh M, Farbood Y, Moghaddam HF. Pathogenic
306 mechanisms following ischemic stroke. Neurol Sci. 2017;38:1167– 1186. doi:
307 10.1007/s10072-017-2938-1

308

Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP. Circulating
 total bilirubin and risk of incident cardiovascular disease in the general population.
 Arterioscler Thromb Vasc Biol. 2015;35:716–724. doi:
 10.1161/ATVBAHA.114.304929

313

5. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin
level, prevalent stroke, and stroke outcomes: nhanes 1999-2004. Am J Med.
2008;121:781–788 e781. doi: 10.1016/j.amjmed.2008.03.045

317

6. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent
predictor of stroke incidence: a prospective study in Korean men and women. Stroke.
2009;40:3422–3427. doi: 10.1161/STROKEAHA.109.560649

321

7. Oda E, Kawai R. A possible cross-sectional association of serum total bilirubin 322 with coronary heart disease and stroke in a Japanese health screening population. 323 Heart Vessels. 2012;27:29-36. doi: 10.1007/s00380-011-0123-7 324 325 8. Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin 326 327 reductase antioxidant cycle. Pediatrics. 2004;113:1776-1782. doi: 10.1542/peds.113.6.1776 328 329 9. Gazzin S, Vitek L, Watchko J, Shapiro SM, Tiribelli C. A novel perspective on the 330 biology of bilirubin in health and disease. Trends Mol Med. 2016;22:758-768. doi: 331 10.1016/j.molmed.2016.07.004 332 333 10. Lee SJ, Jee YH, Jung KJ, Hong S, Shin ES, Jee SH. Bilirubin and Stroke Risk 334 Using a Mendelian Randomization Design. Stroke. 2017 May;48(5):1154-1160. doi: 335 10.1161/STROKEAHA.116.015083. 336 337 11. Choi Y, Lee SJ, Spiller W, Jung KJ, Lee JY, Kimm H, Back JH, Lee S, Jee SH. 338 Causal Associations Between Serum Bilirubin Levels and Decreased Stroke Risk: A 339 Two-Sample Mendelian Randomization Study. Arterioscler Thromb Vasc Biol. 2020 340 Feb;40(2):437-445. doi: 10.1161/ATVBAHA.119.313055. 341 342 12. Kim Y, Han B-G, KoGES group. Cohort Profile: The Korean Genome and 343 Epidemiology Study (KoGES) Consortium. Int J Epidemiol. 2017 Apr 1;46(2):e20. doi: 344 10.1093/ije/dyv316. 345

346	13. Jee YH, Emberson J, Jung KJ, Lee SJ, Lee S, Back JH, Hong S, Kimm H,
347	Sherliker P, Jee SH, Lewington S.Cohort Profile: The Korean Cancer Prevention
348	Study-II (KCPS-II) Biobank.Int J Epidemiol. 2018 Apr 1;47(2):385-386f. doi:
349	10.1093/ije/dyx226.
350	14. Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T,
351	Tamakoshi A, Yamagata Z, Mushiroda T, et al. BioBank Japan Cooperative Hospital
352	Group; Kubo M. Overview of the BioBank Japan Project: Study design and profile.
353	J Epidemiol. 2017; 27(3S):S2-S8. doi: 10.1016/j.je.2016.12.005. Epub 2017 Feb 8.
354	
355	15. O'Brien L, et al. Biliverdin reductase isozymes in metabolism. Trends Endocrinol
356	Metab. 2015;26(4):212–20. [PMC free article] [PubMed] [Google Scholar]
357	
358	16. Tomaro ML, Batlle AM. Bilirubin: its role in cytoprotection against oxidative
359	stress. Int J Biochem Cell Biol. 2002;34(3):216–20. [PubMed] [Google Scholar]
360	
361	17. Sundararaghavan VL, Sindhwani P, Hinds TD., Jr Glucuronidation and UGT
362	isozymes in bladder: new targets for the treatment of uroepithelial
363	carcinomas? Oncotarget. 2016 [PMC free article] [PubMed] [Google Scholar]
364	
365	18. Kwak JY, Takeshige K, Cheung BS, Minakami S: Bilirubin inhibits the activation
366	of superoxide-producing NADPH oxidase in a neutrophil cell-free system. Biochimica
367	et biophysica acta, 1991; 1076: 369-373 [PubMed] [Google Scholar]
368	
369	19. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN: Bilirubin is an
370	antioxidant of possible physiological importance. Science, 1987; 235; 1043-1046

371 [PubMed] [Google Scholar]

20. Li Y, Meng SY, Meng CC, Yu WG, Wang RT. Decreased serum bilirubin is
associated with arterial stiffness in men. Nutr Metab Cardiovasc Dis. 2013;23:375–
381. doi: 10.1016/j.numecd.2011.09.004

375

21. Mahabadi AA, Lehmann N, Möhlenkamp S, Kälsch H, Bauer M, Schulz R,
Moebus S, Jöckel KH, Erbel R, Heusch G. Association of bilirubin with coronary
artery calcification and cardiovascular events in the general population without
known liver disease: the Heinz Nixdorf Recall study. Clin Res Cardiol.
2014;103:647–653. doi: 10.1007/s00392-014-0697-z

381

22. Li RY, Cao ZG, Zhang JR, Li Y, Wang RT. Decreased serum bilirubin is
associated with silent cerebral infarction. Arterioscler Thromb Vasc Biol.
2014;34:946–951. doi: 10.1161/ATVBAHA.113.3030038

23. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total
bilirubin level, prevalent stroke, and stroke outcomes: nhanes 1999-2004. Am J Med.
2008;121:781–788 e781. doi: 10.1016/j.amjmed.2008.03.045

388

389 24. Baranano DE, Rao M, Ferris CD, Snyder SH: Biliverdin reductase: a major

390 physiologic cytoprotectant. Proceedings of the National Academy of Sciences of the

391 United States of America, 2002; 99: 16093-16098 [PMC free

392 <u>article</u>] [PubMed] [Google Scholar]

393

394 25. Neuzil J, Stocker R: Bilirubin attenuates radical-mediated damage to serum

albumin. FEBS letters, 1993; 331: 281-284 [PubMed] [Google Scholar]

26. Minetti M, Mallozzi C, Di Stasi AM, Pietraforte D: Bilirubin is an effective

396

397

398	antioxidant of peroxynitrite-mediated protein oxidation in human blood
399	plasma. Archives of biochemistry and biophysics, 1998; 352: 165-174
400	[PubMed] [Google Scholar]
401	
402	27. Lanone S, Bloc S, Foresti R, Almolki A, Taille C, Callebert J, Conti M, Goven D,
403	Aubier M, Dureuil B, El-Benna J, Motterlini R, Boczkowski J: Bilirubin decreases
404	nos2 expression via inhibition of NAD(P)H oxidase: implications for protection
405	against endotoxic shock in rats. FASEB journal: official publication of the Federation
406	of American Societies for Experimental Biology, 2005; 19: 1890-1892
407	[PubMed] [Google Scholar]
408	
409	28. Stocker R, Peterhans E: Synergistic interaction between vitamin E and the bile
410	pigments bilirubin and biliverdin. Biochimica et biophysica acta, 1989; 1002: 238-244
411	[PubMed] [Google Scholar]
412	
413	29. Neuzil J, Stocker R: Free and albumin-bound bilirubin are efficient co-
414	antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid
415	peroxidation. The Journal of biological chemistry, 1994; 269: 16712-16719
416	[PubMed] [Google Scholar]
417	
418	

419	Table 1. Causal effect of total bilirubin on ischemic	stroke
-----	-------------------------------------------------------	--------

	KoGES (total bilirubin), BBJ (ischemic stroke)		KCPS-II (total bilirubin), BBJ (ischemic stroke)	
	IVW method, OR (95% CI)	Р	IVW method, OR (95% CI)	Р
Crude two sample MR	0.86 (0.75-0.98)	0.0294	0.87 (0.77-0.99)	0.0652
MVMR				
Adjusted for LDL	0.86 (0.76-0.96)	0.0097	0.89 (0.79-1.01)	0.0669
Adjusted for HDL	0.82 (0.73-0.93)	0.0020	0.88 (0.79-0.99)	0.0326
Adjusted for TG*	0.99 (0.99-1.00)	0.0545	0.87 (0.78-0.98)	0.0174
Adjusted for LDL and HDL	0.96 (0.75-1.23)	0.7520	0.95 (0.81-1.12)	0.5259
Adjusted for LDL and TG	0.97 (0.76-1.23)	0.7910	0.91 (0.79-1.05)	0.2009
Adjusted for HDL and TG	0.84 (0.65-1.08)	0.1751	0.94 (0.82-1.09)	0.4217
Adjusted for LDL, HDL and TG	0.99 (0.78-1.25)	0.9070	0.94 (0.82-1.08)	0.3682
Adjusted for LDL, HDL, TG and SBP	0.93 (0.76-1.15)	0.5138	0.95 (0.84-1.08)	0.4658
Adjusted for LDL, TG and SBP	0.87 (0.64-1.19)	0.3891	0.92 (0.81-1.05)	0.2435
Adjusted for LDL, TG, SBP and FSG	0.90 (0.68-1.20)	0.4877	0.92 (0.81-1.05)	0.2136
Adjusted for LDL, TG, and FSG	0.83 (0.65-1.05)	0.1249	0.91 (0.79-1.04)	0.1720

KoGES, Korean Genome Epidemiologic Study; KCPS-II, Korean Cancer Prevention Study-II; BBJ, Biobank of Japan; IVW, inverse variance weighted

method; OR, odds ratio; CI, confidence interval; MVMR, multivariable mendelian randomization; LDL, low density lipoprotein; HDL, high density lipoprotein; TG, triglyceride; SBP, systolic blood pressure; FBS, fasting serum glucose

423 Table 2. Causal effect of direct bilirubin on ischemic s	stroke
--------------------------------------------------------------	--------

	KoGES (direct bilirubin), BBJ (ischemic stroke)		KCPS-II (direct bilirubin), BBJ (ischemic stroke)	
	IVW method, OR (95% CI)	Р	IVW method, OR (95% CI)	Р
Crude two sample MR	0.67 (0.45-1.00)	0.0493	0.65 (0.43-0.97)	0.0335
MVMR				
Adjusted for LDL	0.94 (0.55-1.60)	0.8173	0.64 (0.46-0.89)	0.0093
Adjusted for HDL	0.90 (0.52-1.56)	0.7202	0.65 (0.47-0.91)	0.0125
Adjusted for TG*	0.80 (0.47-1.36)	0.4136	0.64 (0.46-0.88)	0.0064
Adjusted for LDL and HDL	0.81 (0.37-1.77)	0.5987	0.72 (0.43-1.19)	0.2034
Adjusted for LDL and TG	1.02 (0.46-2.25)	0.9557	0.91 (0.56-1.46)	0.6940
Adjusted for HDL and TG	1.34 (0.73-2.46)	0.3469	0.84 (0.47-1.52)	0.5728
Adjusted for LDL, HDL and TG	0.72 (0.41-1.27)	0.2619	0.92 (0.59-1.45)	0.7304
Adjusted for LDL, HDL, TG and SBP	0.88 (0.49-1.60)	0.6847	0.94 (0.61-1.44)	0.7082
Adjusted for LDL, TG and SBP	0.97 (0.53-1.80)	0.9346	0.88 (0.57-1.36)	0.5563
Adjusted for LDL, TG, SBP and FSG	1.63 (0.96-2.77)	0.0727	0.88 (0.58-1.34)	0.5521
Adjusted for LDL, TG, and FSG	1.41 (0.85-2.31)	0.1784	0.91 (0.58-1.44)	0.6992

KoGES, Korean Genome Epidemiologic Study; KCPS-II, Korean Cancer Prevention Study-II; BBJ, Biobank of Japan; IVW, inverse variance weighted

method; OR, odds ratio; CI, confidence interval; MVMR, multivariable mendelian randomization; LDL, low density lipoprotein; HDL, high density lipoprotein; TG, triglyceride; SBP, systolic blood pressure; FBS, fasting serum glucose

427 Table 3. Causal effect of indirect bilirubin on ischemic st	roke
-----------------------------------------------------------------	------

	KoGES (direct bilirubin), BBJ (ischemic stroke)		KCPS-II (direct bilirubin), BBJ (ischemic stroke)	
	IVW method, OR (95% CI)	Р	IVW method, OR (95% CI)	Р
Crude two sample MR	0.81 (0.68-0.97)	0.0253	0.84 (0.70-1.01)	0.0598
MVMR				
Adjusted for LDL	0.81 (0.65-1.02)	0.0800	0.84 (0.72-0.98)	0.0288
Adjusted for HDL	0.88 (0.71-1.08)	0.2262	0.85 (0.72-1.00)	0.0487
Adjusted for TG*	0.85 (0.69-1.06)	0.1526	0.82 (0.70-0.96)	0.0149
Adjusted for LDL and HDL	0.94 (0.62-1.44)	0.7936	0.87 (0.68-1.11)	0.2604
Adjusted for LDL and TG	0.98 (0.69-1.39)	0.8989	0.74 (0.55-0.99)	0.0429
Adjusted for HDL and TG	0.99 (0.63-1.57)	0.9868	0.87 (0.65-1.16)	0.3455
Adjusted for LDL, HDL and TG	0.79 (0.58-1.06)	0.1192	0.74 (0.56-0.98)	0.0355
Adjusted for LDL, HDL, TG and SBP	0.95 (0.70-1.30)	0.7647	0.78 (0.60-1.01)	0.0657
Adjusted for LDL, TG and SBP	1.14 (0.73-1.78)	0.5718	0.77 (0.59-0.99)	0.0505
Adjusted for LDL, TG, SBP and FSG	0.99 (0.99-1.00)	0.4297	0.76 (0.59-0.98)	0.0386
Adjusted for LDL, TG, and FSG	0.93 (0.60-1.42)	0.7384	0.75 (0.57-0.98)	0.0348

KoGES, Korean Genome Epidemiologic Study; KCPS-II, Korean Cancer Prevention Study-II; BBJ, Biobank of Japan; IVW, inverse variance weighted

method; OR, odds ratio; CI, confidence interval; MVMR, multivariable mendelian randomization; LDL, low density lipoprotein; HDL, high density lipoprotein; TG, triglyceride; SBP, systolic blood pressure; FBS, fasting serum glucose



